Mithra and Fuji announce approval of NEXTSTELLIS™ in Thailand

24 October 2022 – 7:30 CET – Tokyo, Japan and Liege, Belgium Fuji Pharma Co., Ltd. (Tokyo Stock Exchange:4554, “Fuji”) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA, “Mithra”) today are pleased to announce that OLIC (Thailand) Limited (“OLIC”), a subsidiary of Fuji, has obtained the approval of import license for NEXTSTELLIS™, a novel combination contraceptive containing estetrol and drospirenone (“Product”), for the indication of Contraception. OLIC anticipates the commercial launch of NEXTSTELLIS™ contraceptive pill in Thailand by the end of 2023.

The Product combines the native and selective estrogen, estetrol (E4) with drospirenone (DRSP). Estetrol has been confirmed to act selectively on estrogen receptors, and this selectivity is expected to provide a variety of benefits to the patients. The Product is already commercialized globally, including major markets such as the US, Canada, Australia and several European countries. Under the terms of the agreement signed in August 2016, Fuji has obtained the development and commercialization rights of the Product in Japan and ASEAN countries. A total oral contraceptive market of ASEAN is around EUR 182 million annual sales. In Japan, the development name of the Product is FSN-013, and Fuji is currently conducting Phase III clinical trials for FSN-013 for the indication of “Dysmenorrhea” and “Improvement effect on pain associated with endometriosis”.

OLIC is one of the largest contract manufacturing organizations (CMO) in the Southeast Asia and is in the middle of transformation from a pure CMO company to a new hybrid company with CMO and pharmaceutical business with own brand products. This approval is the first step in that direction. This approval was conducted for the purpose of importing and selling the Product by OLIC in Thailand.

Takayuki Iwai, President & Chief Executive Officer of Fuji, commented: This is an exciting opportunity and a significant global step for Fuji pharma group. The approval will enable OLIC to make NEXTSTELLIS™ available to women across Thailand by the end of 2023. After which, we plan to market the Product in other ASEAN countries through the collaboration with partner companies. Fuji will accelerate the development of the Product to provide patients with new treatment options that contain Estetrol.”

Leon Van Rompay, CEO Mithra Women’s Health, commented: We are pleased to announce this additional marketing authorization for our contraceptive pill in Asia, following the recent approvals for Taiwan and Hong Kong obtained last month. We would like to thank our partner Fuji for this fruitful collaboration, which translates today into an important milestone for our Product in these territories which, considering the two potential indications of contraception and dysmenorrhea, represents a real market opportunity.”


Please read this carefully as it applies to all persons who visit this website. The following pages contain information relating to an offering and/or admission to trading on a regulated market in relation to securities of Mithra Pharmaceuticals SA ("Mithra Pharmaceuticals"). This information may not be accessed by residents of certain countries based on applicable securities law regulations. Accordingly, if you wish to access this part of the website you must first inform yourself about and then observe the statutory and regulatory requirements applicable to you and to your jurisdiction. In order to establish whether or not you may view the information and documents please read the disclaimer below in full.


This website and the information contained herein or to which it gives access are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the "United States"), Australia, Japan or South Africa, and do not constitute, or form part of, an offer or invitation to sell or issue, or a solicitation of an offer or invitation to purchase or subscribe for, nor shall there be any sale or purchase of, any securities of Mithra Pharmaceuticals in the United States, Australia, Japan or South Africa or in any other jurisdiction in which such offer, invitation, solicitation, sale, issue, purchase or subscription would be unlawful prior to registration, unless an exemption from registration or qualification under the securities laws of any such jurisdiction is applicable. The securities of Mithra Pharmaceuticals referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act. There will be no public offering of Mithra Pharmaceuticals' securities in the United States.

All persons residing outside of the United States, Australia, Canada, Japan and South Africa who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. Mithra Pharmaceuticals assumes no responsibility if there is a violation of applicable law and regulations by any person.

No action has been taken by Mithra Pharmaceuticals that would permit an offer of Mithra's securities or the possession or distribution of the materials to which this website gives access or any other offering or publicity material relating to Mithra's securities in any jurisdiction where action for that purpose is required.

Mithra Pharmaceuticals has not authorised any public offering in any Member State of the European Economic Area. With respect to any Member State of the European Economic Area that has implemented Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended from time to time (together with any applicable implementing measures in such Member State, the "Prospectus Regulation"), this website and the information contained herein, or to which it gives access, is only addressed to, and is only directed at, qualified investors in that Member State within the meaning of the Prospectus Regulation.

In addition, in the United Kingdom, this website and the information contained herein, or to which it gives access, is addressed to, and directed only at: (a) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), and (b) high net worth entities, and other persons to whom they may otherwise lawfully be communicated, falling within article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). In the United Kingdom, any investment or investment activity to which this website and the information contained herein, or to which it gives access, relates, is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this website and the information contained herein, or to which it gives access.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Access to electronic versions of these materials is being made available on this webpage by Mithra Pharmaceuticals in good faith and for information purposes only.

By checking the acceptance box below, you confirm and certify that: You are not a resident of or physically present in the United States, Australia, Canada, Japan or South Africa or any other restricted jurisdiction, and that you are either: (a) a resident of, and domiciled in, a Member State of the European Economic Area and a qualified investor within the meaning of the Prospectus Regulation, (b) a resident of, and domiciled in, the United Kingdom, a qualified investor within the meaning of the Prospectus Regulation and a Relevant Person, or (c) otherwise authorised to access this information pursuant to applicable laws or regulations.